Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus

Summary.  Background: Evidence suggests the wide variation in platelet response within the population is genetically controlled. Unraveling the complex relationship between sequence variation and platelet phenotype requires accurate and reproducible measurement of platelet response. Objective: To develop a methodology suitable for measuring signaling pathway‐specific platelet phenotype, to use this to measure platelet response in a large cohort, and to demonstrate the effect size of sequence variation in a relevant model gene. Methods: Three established platelet assays were evaluated: mobilization of [Ca2+]i, aggregometry and flow cytometry, each in response to adenosine 5′‐diphosphate (ADP) or the glycoprotein (GP) VI‐specific crosslinked collagen‐related peptide (CRP). Flow cytometric measurement of fibrinogen binding and P‐selectin expression in response to a single, intermediate dose of each agonist gave the best combination of reproducibility and inter‐individual variability and was used to measure the platelet response in 506 healthy volunteers. Pathway specificity was ensured by blocking the main subsidiary signaling pathways. Results: Individuals were identified who were hypo‐ or hyper‐responders for both pathways, or who had differential responses to the two agonists, or between outcomes. 89 individuals, retested three months later using the same methodology, showed high concordance between the two visits in all four assays (r2 = 0.872, 0.868, 0.766 and 0.549); all subjects retaining their phenotype at recall. The effect of sequence variation at the GP6 locus accounted for ∼35% of the variation in the CRP‐XL response. Conclusion: Genotyping‐phenotype association studies in a well‐characterized, large cohort provides a powerful strategy to measure the effect of sequence variation in genes regulating the platelet response.

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[3]  F. Gries,et al.  Platelet Membrane Activation Markers Are Predictive for Increased Risk of Acute Ischemic Events After PTCA , 1993, Circulation.

[4]  Z. Ruggeri,et al.  Von Willebrand factor, platelets and endothelial cell interactions , 2003, Journal of thrombosis and haemostasis : JTH.

[5]  W. Ouwehand,et al.  The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. , 2003, Blood.

[6]  J. Erikssen,et al.  Blood Platelet Count and Function Are Related to Total and Cardiovascular Death in Apparently Healthy Men , 1991, Circulation.

[7]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[8]  C. Gachet,et al.  The P2 receptors in platelet function. , 2005, Seminars in thrombosis and hemostasis.

[9]  N. Arber,et al.  Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.

[10]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[11]  T. Kunicki The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  P. Bray,et al.  Aggregometry detects platelet hyperreactivity in healthy individuals. , 2005, Blood.

[13]  G. FitzGerald Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.

[14]  W. Ouwehand,et al.  Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in‐depth exon resequencing and genotyping with tag single nucleotide polymorphisms , 2006, Journal of thrombosis and haemostasis : JTH.

[15]  M. Hoylaerts,et al.  The platelet ATP and ADP receptors. , 2006, Current pharmaceutical design.

[16]  N. Samani,et al.  Dimorphism in the P2Y1 ADP Receptor Gene Is Associated With Increased Platelet Activation Response to ADP , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R H Myers,et al.  Genetic and Environmental Contributions to Platelet Aggregation: The Framingham Heart Study , 2001, Circulation.

[18]  P. Perrotta,et al.  Transcript profiling of human platelets using microarray and serial analysis of gene expression. , 2003, Blood.

[19]  A. Goodall,et al.  ADP causes partial degranulation of platelets in the absence of aggregation , 1994, British journal of haematology.

[20]  P. Mannucci,et al.  Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. , 1990, Blood.

[21]  R. Young,et al.  Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. , 1995, The Biochemical journal.

[22]  M. Hughes,et al.  Adjusting for regression toward the mean when variables are normally distributed , 1997, Statistical methods in medical research.

[23]  P. Propping,et al.  Epinephrine‐induced platelet aggregation. A twin study ** , 1984, Clinical genetics.

[24]  S. Bernocco,et al.  Early Events in the Polymerization of Fibrin , 2001, Annals of the New York Academy of Sciences.

[25]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[26]  D. Monroe,et al.  A Cell-based Model of Hemostasis , 2001, Thrombosis and Haemostasis.

[27]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[28]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[29]  Peter Bugert,et al.  Messenger RNA profiling of human platelets by microarray hybridization , 2003, Thrombosis and Haemostasis.

[30]  W. Ouwehand,et al.  Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. , 2007, Blood.

[31]  Fred Charatan US doctors win round in battle for right to negotiate with HMOs , 2000, BMJ : British Medical Journal.

[32]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[33]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[34]  E. Mammen,et al.  Circadian variation in platelet function in healthy volunteers. , 1992, The American journal of cardiology.

[35]  M. Dalby,et al.  Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. , 2000, Platelets.

[36]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[37]  M.C.D. Dalby, S.J. Davidson, J.F. Burman, S.W. Davies Diurnal variation in platelet aggregation with the PFA–100 platelet function analyser , 2000 .

[38]  O. McCarty,et al.  GPVI and integrin αIIbβ3 signaling in platelets , 2005, Journal of thrombosis and haemostasis : JTH.

[39]  W. Ouwehand,et al.  Platelet genomics and proteomics in human health and disease. , 2005, The Journal of clinical investigation.